Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
22.03
+0.26 (+1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Earnings Preview: Arcturus Therapeutics
March 06, 2024
Via
Benzinga
Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
February 27, 2024
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.
Via
Chartmill
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
February 26, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
February 22, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Is NASDAQ:ARCT suited for growth investing?
February 06, 2024
Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?
Via
Chartmill
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Via
InvestorPlace
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
February 20, 2024
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.
Via
InvestorPlace
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
February 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 05, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics: Q3 Earnings Insights
November 14, 2023
Via
Benzinga
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 23, 2024
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
January 16, 2024
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
December 26, 2023
Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
Via
Chartmill
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023
From
Arcturus Therapeutics
Via
Business Wire
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 04, 2023
Via
Benzinga
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 04, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Why the growth investor may take a look at NASDAQ:ARCT.
December 04, 2023
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
November 28, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
November 27, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 15, 2023
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
Via
Benzinga
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
November 15, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
November 15, 2023
Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 15, 2023
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!
Via
InvestorPlace
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
November 14, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
November 14, 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.